Emkay Global Financial is bullish on Dr. Reddy's has recommended buy rating on the stock with a target price of Rs 6050 in its research report dated October 28, 2020.

Buy Dr Reddy's Laboratories; target of Rs 6000: ICICI Direct

ICICI Direct is bullish on Dr Reddy's Laboratories recommended buy rating on the stock with a target price of Rs 6000 in its research report dated October 29, 2020.

Accumulate Dr. Reddy’s laboratories; target of Rs 5418 KR Choksey

KR Choksey recommended accumulate rating on Dr. Reddy’s laboratories with a target price of Rs 5418 in its research report dated October 30, 2020.

Accumulate Dr Reddy's Laboratories; target of Rs 5414: Dolat Capital Market

Dolat Capital Market recommended accumulate rating on Dr Reddy's Laboratories with a target price of Rs 5414 in its research report dated October 28, 2020.

Buy Dr. Reddy's Laboratories; target of Rs 5964: Prabhudas Lilladher

Prabhudas Lilladher is bullish on Dr. Reddy's Laboratories has recommended buy rating on the stock with a target price of Rs 5964 in its research report dated October 29, 2020.

Dr Reddy’s: Better US prospects to sustain valuations

Dr Reddy's US growth prospects have improved after its recent settlement with Bristol Myers Squibb to launch an oncology drug

Accumulate Dr. Reddy's Laboratories; target of Rs 5648: Prabhudas Lilladher

Prabhudas Lilladher recommended accumulate rating on Dr. Reddy's Laboratories with a target price of Rs 5648 in its research report dated October 05, 2020.

Cadila: a formidable play in Covid times and beyond

Cadila is not only a credible Indian pharma striving for a Covid solution, but on a longer time scale is an interesting watch in the large-cap space witnessing a significant transformation in product portfolio.

Accumulate Dr. Reddy's Laboratories; target of Rs 5648: Prabhudas Lilladher

Prabhudas Lilladher recommended accumulate rating on Dr. Reddy's Laboratories with a target price of Rs 5648 in its research report dated September 24, 2020.

Buy Dr Reddy’s Laboratories; target of Rs 5710: ICICI Direct

ICICI Direct is bullish on Dr Reddy’s Laboratories recommended buy rating on the stock with a target price of Rs 5710 in its research report dated September 18, 2020.

Hold Dr. Reddy's Lab; target of Rs 5325: Emkay Global Financial

Emkay Global Financial recommended hold rating on Dr. Reddy's Lab with a target price of Rs 5325 in its research report dated September 17, 2020.

Accumulate Dr. Reddy's Laboratories; target of Rs 4834: Dolat Capital

Dolat Capital recommended accumulate rating on Dr. Reddy's Laboratories with a target price of Rs 4834 in its research report dated September 17, 2020.

Hold Dr. Reddy's; target of Rs 4550: Emkay Global Financial

Emkay Global Financial recommended hold rating on Dr. Reddy's with a target price of Rs 4550 in its research report dated September 07, 2020.

Hold Dr. Reddy's; target of Rs 4550: Emkay Global Financial

Emkay Global Financial recommended hold rating on Dr. Reddy's with a target price of Rs 4550 in its research report dated July 29, 2020.

Neutral Dr Reddy’s Labs; target of Rs 4600: Motilal Oswal

Motilal Oswal recommended Neutral rating on Dr Reddy’s Labs with a target price of Rs 4600 in its research report dated July 30, 2020.

Hold Dr. Reddy's Laboratories; target of Rs 4326: Prabhudas Lilladher

Prabhudas Lilladher recommended Hold rating on Dr. Reddy's Laboratories with a target price of Rs 4326 in its research report dated July 29, 2020.

Accumulat Dr Reddy's Laboratories; target of Rs 4721: Dolat Capital

Dolat Capital recommended accumulat rating on Dr Reddy's Laboratories with a target price of Rs 4721 in its research report dated July 29, 2020.

Reduce Dr. Reddy’s Labs; target of Rs 3940: HDFC Securities

HDFC Securities recommended reduce rating on Dr. Reddy’s Labs with a target price of Rs 3940 in its research report dated July 30, 2020.

Buy Dr Reddy's Laboratories; target of Rs 5000: ICICI Direct

ICICI Direct is bullish on Dr Reddy's Laboratories has recommended buy rating on the stock with a target price of Rs 5000 in its research report dated July 30, 2020.

Dr Reddy’s investment case bolstered by improved margins and product launch guidance

Key drag for the Dr Reddy's is India business. Compared to its peers, it has a low revenue share in India and that too is majorly in the acute category

Buy Dr Reddy's Laboratories; target of Rs 4615: ICICI Direct

ICICI Direct is bullish on Dr Reddy's Laboratories has recommended buy rating on the stock with a target price of Rs 4615 in its research report dated May 21, 2020.

Accumulate Dr. Reddy's Laboratories; target of Rs 4326: Prabhudas Lilladher

Prabhudas Lilladher recommended accumulate rating on Dr. Reddy's Laboratories with a target price of Rs 4326 in its research report dated May 21, 2020.

Hold Dr Reddy's Laboratories target of Rs 3255: ICICI Direct

ICICI Direct recommended hold rating on Dr Reddy's Laboratories with a target price of Rs 3255 in its research report dated January 28, 2020.